The CorCinch - Functional Mitral Valve Regurgitation (FMR) Study

Purpose

This is a multi-center, non-randomized, prospective Early Feasibility Study to evaluate the AccuCinch® Ventricular Restoration System in patients with symptomatic heart failure and concomitant functional mitral regurgitation that have stable symptoms on guideline-directed medical therapy

Conditions

  • Heart Failure
  • Mitral Valve Insufficiency
  • Cardiomyopathies

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Study patient is at least 18-years old - Severity of FMR: ≥ Moderate (i.e., 2+, according to Stone et al Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 1: Clinical Trial Design Principles. A Consensus Document from the Mitral Valve Academic Research Consortium11; and 2003 ASE Guidelines for grading mitral regurgitation10) - Ejection Fraction: ≥20 to ≤60% - Symptom Status: NYHA II-IV (i.e., ambulatory) - Treatment and compliance with optimal guideline directed medical therapy for heart failure for at least 1 month - Surgical risk: Subject is eligible for cardiac surgery (specific risk score or comorbidities should demonstrate high risk features, as determined by the Heart Team) - Completion of all qualifying diagnostic and functional tests and agrees to comply with study follow-up schedule

Exclusion Criteria

  • Patients with significant organic mitral valve pathology (e.g. myxomatous degeneration, mitral valve prolapse or flail leaflets) - Myocardial infarction or any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid surgery within 30 days - Prior surgical, transcatheter, or percutaneous mitral valve intervention - Untreated clinically significant coronary artery disease (CAD) requiring revascularization - Hemodynamic instability: Hypotension (systolic pressure <90 mmHg) or requirement for inotropic support or mechanical hemodynamic support - Any planned cardiac surgery or interventions within the next 6 months (including right heart procedures) - NYHA class IV (i.e., non-ambulatory) or American College of Cardiology (ACC)/American Heart Association (AHA) Stage D heart failure - Fixed pulmonary artery systolic pressure >70 mmHg - Severe tricuspid regurgitation (per ASE guidelines and graded by the Echo Core Lab) - Modified Rankin Scale ≥ 4 disability - Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or any other structural heart disease causing heart failure other than dilated cardiomyopathy of either ischemic or non-ischemic etiology. - Anatomical pathology/constraints preventing appropriate access/implant of the AccuCinch® Ventricular Restoration System (e.g., femoral arteries will not support a 20F system) - Renal insufficiency (i.e., eGFR of <30ml/min/1.73m2; Stage 4 or 5 CKD) - Moderate or severe aortic valve stenosis or regurgitation or aortic valve prosthesis - Fluoroscopic or echocardiographic evidence of severe aortic arch calcification, mobile aortic atheroma, intracardiac mass, thrombus or vegetation - Active bacterial endocarditis

Study Design

Phase
N/A
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Device Feasibility
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
AccuCinch® Ventricular Restoration System
  • Device: Mitral valve repair

More Details

Status
Unknown status
Sponsor
Ancora Heart, Inc.

Study Contact

Detailed Description

Device name changed from AccuCinch® Ventricular Repair System to AccuCinch® Ventricular Restoration System, FDA Approval Date 08Aug2020